Medication info
Amoratanal Tablet 5/80/10 mg

Amoratanal Tablet 5/80/10 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
CMG Pharmaceuticals Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202108064 · Approved 2021.12.21 · Insurance code 648604380

Summary

Main use
Treats hypertension, improves dyslipidemia, and inhibits the progression of arteriosclerosis and the risk of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Older adults aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal failure: No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal failure. 4. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
CMG Pharmaceuticals Co., Ltd.

Efficacy & effects

Treats hypertension, improves dyslipidemia, and inhibits the progression of arteriosclerosis and the risk of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary atypical beta-lipoproteinemia
  • coronary heart disease risk factors
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • early family history of coronary heart disease
View approved original text

This drug is used for patients with essential hypertension whose blood pressure is not well controlled, combining amlodipine and valsartan. It is also suitable for patients receiving rosuvastatin simultaneously. Rosuvastatin is used as an adjunctive treatment when dietary therapy is ineffective for patients with hypercholesterolemia and dyslipidemia, and particularly helps patients with familial hypercholesterolemia. In addition, rosuvastatin contributes to delaying the progression of atherosclerosis and reducing the risk of cardiovascular diseases, strokes, and myocardial infarctions. Therefore, this drug effectively improves cardiovascular health through the management of blood pressure and cholesterol.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher); however, do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Older adults aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal failure: No dose adjustment is necessary in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal failure. 4. Patients with hepatic failure: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, and should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug or similar medications, pregnant or breastfeeding women, patients with severe liver or kidney diseases, or those with a history of certain heart diseases or angioedema should not take this medication. Patients with sodium or fluid depletion must correct their condition before taking this drug, as hypotension may occur during treatment necessitating careful observation. Patients with high potassium levels or taking other medications that may increase potassium should frequently monitor their potassium levels. Patients with kidney problems or kidney transplant recipients should closely monitor their kidney function when taking this drug. If symptoms of angioedema occur, discontinue use immediately and do not re-administer. Patients with heart failure or those post-myocardial infarction require kidney function evaluation when taking this medication. There is no special dose adjustment needed for the elderly, but those over 75 years old should start at a lower dose and gradually increase. Dizziness or fatigue may occur during treatment, so take care when driving or operating machinery. This drug may affect the liver and muscles, necessitating periodic observation of liver function tests and muscle-related symptoms, and immediate consultation with a doctor if symptoms like muscle pain or weakness appear. Drug interactions may occur when combined with other medications, especially with diuretics, potassium-sparing agents, certain antibiotics or antifungals, and immunosuppressants. Therefore, adhere to professional guidance. Pregnant women or those planning a pregnancy should not take this medication, and breastfeeding mothers should avoid it or discontinue breastfeeding. This medication is not recommended for children under 18 years old. In the event of an overdose, symptoms such as hypotension, shock, and impaired cardiac function may appear, so immediate medical assistance should be sought, and emergency treatment may be necessary.

Side effects

  • peripheral edema
  • heat sensation
  • increased ALT
  • increased AST
  • increased serum creatinine
  • flank pain
  • neck pain
  • dizziness
  • hypesthesia
  • nasopharyngitis
Show 156 more
  • rash
  • nasopharyngitis
  • influenza
  • hypersensitivity
  • visual impairment
  • anxiety
  • headache
  • drowsiness
  • orthostatic dizziness
  • paresthesia
  • vertigo
  • tinnitus
  • tachycardia
  • palpitations
  • syncope
  • orthostatic hypotension
  • hypotension
  • cough
  • oropharyngeal and laryngeal pain
  • diarrhea
  • nausea
  • abdominal pain
  • constipation
  • dry mouth
  • erythema
  • hyperhidrosis
  • rash
  • itching
  • joint edema
  • low back pain
  • arthritis
  • muscle cramps
  • lethargy
  • pollakiuria
  • polyuria
  • erectile dysfunction
  • edema
  • periorbital edema
  • facial edema
  • fatigue
  • flushing
  • weakness
  • facial flushing
  • chest pain
  • pain
  • nocturia
  • discomfort in the chest
  • abdominal discomfort
  • gastroesophageal reflux disease
  • hypercholesterolemia
  • hypoglycemia
  • thrombocytopenia
  • leukopenia
  • allergic reaction
  • hyperglycemia
  • insomnia
  • mood changes
  • tremor
  • taste disturbance
  • peripheral neuropathy
  • hypertonicity
  • arrhythmia
  • bradycardia
  • atrial fibrillation
  • ventricular tachycardia
  • vasculitis
  • dyspnea
  • rhinitis
  • vomiting
  • dyspepsia
  • pancreatitis
  • gastritis
  • gingival hyperplasia
  • hepatitis
  • jaundice
  • alopecia
  • purpura
  • skin depigmentation
  • photosensitivity reaction
  • angioedema
  • urticaria
  • erythema multiforme
  • Stevens-Johnson syndrome
  • myalgia
  • urinary disturbance
  • nocturia
  • gynecomastia
  • pain
  • malaise
  • weight loss
  • weight gain
  • decreased hemoglobin
  • decreased hematocrit
  • neutropenia
  • serum disease
  • increased serum potassium
  • vasculitis
  • elevated liver function tests
  • bullous dermatitis
  • myalgia
  • renal failure
  • renal injury
  • increased serum creatinine
  • insomnia
  • decreased libido
  • pharyngitis
  • rhinitis
  • sinusitis
  • upper respiratory infection
  • viral infection
  • angioedema
  • polyneuropathy
  • amnesia
  • peripheral neuropathy
  • cough
  • dyspnea
  • diarrhea
  • thrombocytopenia
  • jaundice
  • hepatitis
  • increased transaminases
  • lupus-like syndrome
  • muscle rupture
  • immune-mediated necrotizing myopathy
  • hematuria
  • edema
  • depression
  • sleep disturbances
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • fatal and non-fatal liver failure
  • cognitive decline
  • forgetfulness
  • amnesia
  • memory impairment
  • confusion
  • myasthenia gravis
  • oculomotor weakness
  • increased CK
  • constipation
  • nausea
  • abdominal pain
  • weakness
  • arthralgia
  • fatigue
  • numbness
  • paresthesia
  • chest discomfort
  • loss of appetite
  • abdominal distension
  • abnormal liver function tests
  • syncope
  • generalized pain
  • muscle cramps
  • gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 to 30 degrees Celsius at room temperature to preserve the drug's efficacy.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.